ID1 and neoplasm: In summary, we speculate that BYJHD exerts its anti-NSCLC activity through the ACVRL-1/Smad/ID-1 axis and the inhibition of CD expression, thereby regulating the tumour microenvironment and inhibiting tumour angiogenesis.